Endocrine Therapies in Breast Cancer

Edited by Aman U. Buzdar

Oxford Oncology Library

Provides a summary of the latest evidence based and practical information on the use of endocrine therapies in the management of breast cancer
Covers an extensive range of endocrine therapies currently available to clinicians
Includes chapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer
Portable, accessible format for quick-reference
Helpful "Key Points" sections at the start of each chapter
2-colour printing throughout

Endocrine Therapies in Breast Cancer

Edited by Aman U. Buzdar

Description

Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging indications for the aromatase inhibitors are providing clinicans (and patients) with alternative treatment options with differing side effect profiles.

Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists from the MD Anderson Cancer Center, the book covers the range of endocrine therapies currently available to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes useful chapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer.

This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer.

Endocrine Therapies in Breast Cancer

Edited by Aman U. Buzdar

Oxford Oncology Library

1:Selection of patients for endocrine therapies, Dr W. Fraser Symmans and Dr Lajos Pusztai
2:Ovarian ablation, Kellie L. Jones
3:Antiestrogens, Professor John F. Forbes
4:Aromatase inhibitors in early and advanced disease, Laura B. Michaud
5:Fulvestrant - Metastatic disease, Professor John FR Roberston, Mr Kwok-Leung Cheung and Mr Amit Agrawal
6:Progestins and androgens, Janet Espirito
7:Combined endocrine and chemotherapy, Professor Aman U. Buzdar
8:Hormonal replacement therapy in patients with prior history of breast cancer, Dr Rena V. Sellin
9:Prevention, Professor Jack Cuzick

Endocrine Therapies in Breast Cancer

Edited by Aman U. Buzdar

Oxford Oncology Library

Author Information

Edited by Aman U. Buzdar, Professor of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA

Contributors:

Mr Amit Agrawal, Research Fellow, University Medical School, Nottingham University Hospitals, Nottingham, UK
Professor Aman U. Buzdar, Professor of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA
Mr Kwok-Leung Cheung, Consultant in General Surgery, University Medical School, Nottingham, UK
Professor Jack Cuzick, Researcher, Cancer Research UK Clinical Centre at Barts and the London, London, UK
Janet Espirito, Clinical Pharmacy Specialist, University of Texas MD Anderson Cancer Center, Houston, USA
Dr Gilbert G. Fareau, Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Center, Houston, USA
Professor John F. Forbes, Professor of Surgical Oncology, University of Newcastle, New South Wales, Australia
Kellie L. Jones, Clinical Pharmacy Specialist, University of Texas MD Anderson Cancer Center, Houston, USA
Laura B. Michaud, Clinical Pharmacy Specialist, University of Texas MD Anderson Cancer Center, Houston, USA
Dr Lajos Pusztai, Associate Professor of Medicine, University of Texas MD Anderson Cancer Center, USA
Professor John FR Roberston, Consultant in General Surgery, University Medical School, Nottingham, UK
Dr Rena V. Sellin, Professor, Endocrine Neoplasia and HD, University of Texas MD Anderson Cancer Center, USA
Dr W. Fraser Symmans, Associate Professor of Pathology, University of Texas MD Anderson Cancer Center, USA